For example, a double transgenic mouse model expressing APP-V7171 and Tau-P301L, develops amyloid pathology similarly to mice transgenic for APP-V7171 alone, whereas tauopathy is dramatically enhanced in the double transgenic compared to mice transgenic for Tau-P301L alone. This evidence concerns the gene MAPT and amyloidosis.